WO2006054710A1 - 最大消化管通過時間改善剤、消化管通過時間改善剤及び大腸癌予防剤 - Google Patents
最大消化管通過時間改善剤、消化管通過時間改善剤及び大腸癌予防剤 Download PDFInfo
- Publication number
- WO2006054710A1 WO2006054710A1 PCT/JP2005/021272 JP2005021272W WO2006054710A1 WO 2006054710 A1 WO2006054710 A1 WO 2006054710A1 JP 2005021272 W JP2005021272 W JP 2005021272W WO 2006054710 A1 WO2006054710 A1 WO 2006054710A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- magnesium
- transit time
- oligosaccharide
- gastrointestinal transit
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention prevents food intake from staying in the gastrointestinal tract, particularly the lower gastrointestinal tract (large intestine) for a long time, and shortens the time until it is discharged from the body without causing stool without anxillary action.
- the present invention relates to a technology that suppresses adverse effects on the human body, particularly the large intestine, caused by harmful spoilage products.
- Burkitt et al. Have a small amount of refined dietary fiber! /, Eat a meal! /, Westerners are likely to have a longer time for food residues to pass through the digestive tract, such as colon cancer. The incidence of large bowel disease is high, while dietary fiber is high! Eating unrefined food! / The short transit time of gastrointestinal tract indicates that Africans rarely have colon disease.
- Cummings et al. Found that there was an inverse correlation between colorectal cancer incidence and defecation volume in a survey of 23 regions in the world. In the Burkitt et al. Study, there is an inverse correlation between the amount of defecation and transit time. For this reason, it is considered that the greater the amount of defecation, the shorter the passage time in the digestive tract and the less likely it is to develop colorectal cancer.
- constipation is the frequency of defecation, for example, if there is no regular defecation, or how many days in a week there is no defecation.
- constipation is not diagnosed with the awareness of food residue passage time in the digestive tract.
- Defecation is defined as the contents of excreta that are congested in the intestinal tract when the burden continues beyond the capacity of the gastrointestinal tract. (Dr. Mitsuo Koda, “If you skipped breakfast, you'll get this.” Shunjusha).
- the state and extent of content congestion in the gastrointestinal tract cannot be estimated from mere defecation frequency, which has been used to diagnose constipation in the past, and it is necessary to directly check the state and extent of congestion.
- constipation drugs or laxatives may not be effective in treating constipation patients, that is, increasing the frequency of defecation, but it does not necessarily increase the digestive and maximum gastrointestinal transit times of food residues that remain for a long time. It cannot be said that it is effective for shortening.
- the use of constipation drugs or laxatives by healthy individuals who are not constipated may cause discomfort such as abdominal distension or weakness due to indigestion. Often accompanied. It is caused by food residues staying in the gastrointestinal tract for a long time by healthy individuals to improve their health by quickly shortening the gastrointestinal transit time and the maximum gastrointestinal transit time without these symptoms.
- No gastrointestinal transit time improving agent or maximum gastrointestinal transit time improving agent capable of preventing various diseases has been known.
- indigestible saccharides and dietary fiber are not digested in the upper digestive tract and are not digested in the lower digestive tract.
- indigestible oligosaccharides have been studied in detail for the action of proliferating colonic bifidobacteria and making the intestinal environment acidic by the action of the short-chain fatty acid produced to improve the intestinal flora.
- the number of bifidobacteria in the large intestine is reduced due to constipation or for some reason, by increasing the number of bifidobacteria by administration of oligosaccharide, the pH in the intestine is lowered and other harmful intestinal bacteria By suppressing the growth and preparing the intestinal environment, it is interpreted that the reduction of harmful spoilage products in the intestine can improve the convenience.
- latitol or lactulose which are indigestible saccharides, reduce ammonia produced by harmful intestinal bacteria, so that they can be used as drugs for improving bowel function and treating symptoms associated with hyperammonemia.
- hyperammonemia the ability to take lactulose powder with a pure content of 97% or more, 19.5 to 39 g a day for adults, 100% lactitol powder with a pure content, 18 to 36 g a day for adults 3 times Divide into two doses. Ratathitol and lactulose are administered in such high doses in people with impaired bowel function, who are prone to colon polyps, and in patients with hepatic encephalopathy due to hyperammonemia.
- magnesium oxalate marketed as a laxative
- 2g per day before or during meals take 3 doses or take 1 dose before going to bed.
- Magnesium oxide 2g is equivalent to 1160 mg of magnesium.
- the strong abdominal action causes side effects such as abdominal fullness and weakness after defecation due to indigestion. hard.
- Non-constipated gastrointestinal transit time or the maximum gastrointestinal transit time can be improved in healthy individuals with normal defecation rather than loose stool, without any deglutition or side effects.
- the dosage of magnesium is not indicated in the Japanese Pharmacopoeia.
- Japanese Patent Application Laid-Open No. 2001-48792 describes a laxative containing an active magnesium oxalate having a specific surface area (BET) force of 21 m 2 Zg or more as an active ingredient.
- activated magnesium oxide 2.4 g Zl00 ml solution was taken to 70 ml per day (974 mg as magnesium) to five monitors, and the laxative effect was confirmed.
- a solution of activated magnesium oxide 2.4 g Zl00 ml, 100 ml of oligosaccharide solution and 40 ml of drinking water is prepared, and 150 ml per day (870 mg as magnesium) is prepared for five monitors. The majesty effect has been confirmed.
- the pharmaceutical dosage is applied only for the duration of the disease by the patient for treatment and should not be applied if a healthy person takes it daily for disease prevention purposes.
- An object of the present invention is to increase the speed and strength of a healthy person who is not constipated, so that the food residue staying in the extinguishing tube for a long time due to overeating or the like does not cause a loose stool without a swallowing action.
- the purpose is to promote the maintenance of health by reducing the harmful effects of harmful spoilage products in the intestines on the human body.
- the present inventor has one or more selected from among non-constipated healthy individuals who have regular stool and are indigestible saccharides, low-viscosity water-soluble dietary fiber, and magnesium compound. Shorten the maximum gastrointestinal transit time and gastrointestinal transit time, which are prolonged due to overeating, etc., without unpleasant side effects such as bloating, vaginal action, loose stool, etc. by using lactulose and acid ⁇ magnesium together The present invention has been completed.
- the present invention relates to the following technique.
- Item 1 A maximum digestive tract transit time improving agent characterized by containing at least one kind of hardly digestible saccharide, low-viscosity water-soluble dietary fiber, and magnesium compound.
- Item 2 Indigestible saccharides are lactulose, galatato-oligosaccharide, raffinose, stachyose, ratatosucrose, furata-oligosaccharide, isomaltoligosaccharide, xylooligosaccharide, palatinose oligosaccharide, difructose anhydride III, sorbitol, maltitol, ratathitol, reduced
- a group power of palatinose and reduced hydrostatic strength is at least one selected, and low-viscosity water-soluble dietary fiber is resistant to digestion dextrin, guagam degradation product, polydextrose, water-soluble soybean polysaccharide, low-molecular alginic acid, and water-soluble corn It is at least one selected from the group consisting of one fiber, and at least a group force consisting of magnesium compound power magnesium oxide, magnesium hydroxide, magnesium silicate, and magnesium carbonate power is also selected.
- Item 3 The maximum gastrointestinal transit time improving agent according to Item 2, comprising lactulose and magnesium oxide.
- Item 4 The maximum gastrointestinal transit time improving agent according to any one of Items 1 to 3, further comprising a calcium compound.
- Item 5 A gastrointestinal transit time improver containing lactulose and magnesium oxide.
- Item 6 The gastrointestinal transit time improving agent according to Item 5, further comprising a calcium compound.
- Item 7 A preventive agent for colorectal cancer comprising lactulose and magnesium oxide.
- Item 8 The colon cancer preventive agent according to Item 7, further comprising a calcium compound.
- Item 9 Reduced maximum gastrointestinal transit time characterized by oral administration of an effective amount to improve the maximum gastrointestinal transit time of any one of indigestible saccharide, low-viscosity water-soluble dietary fiber and magnesium compound How to make.
- Item 10 Oral dosage power per day for indigestible saccharides, low-viscosity water-soluble dietary fiber, and magnesium compounds is 0.8 to 6 g, lg to 10 g, and 40 mg to 600 mg in terms of magnesium, respectively.
- Item 10. A method for reducing the maximum gastrointestinal transit time according to Item 9.
- Indigestible saccharides are lactulose, galatato-oligosaccharide, raffinose, stachyose, latatosucrose, furato-oligosaccharide, isomalt-oligosaccharide, xylo-oligosaccharide, palatinose-oligosaccharide, difructose anhydride III, sorbitol, maltitol, lactitol, reduced
- a group power of palatinose and reduced hydrostatic strength is at least one selected, and low-viscosity water-soluble dietary fiber is indigestible dextrin, guagam degradation product, polydextrose, water-soluble soybean polysaccharide, low-molecular alginic acid, and water-soluble corn fiber It is at least one kind selected from the group consisting of one power and is characterized by at least one kind selected from the group power consisting of magnesium compound power magnesium hydroxide, magnesium hydroxide, magnesium si
- Item 12 A method for preventing colorectal cancer, comprising orally administering an effective amount for preventing colorectal cancer of any one of indigestible saccharides, low-viscosity water-soluble dietary fiber and magnesium compound.
- Item 13 Daily dosage of indigestible saccharides, low-viscosity water-soluble dietary fiber, and magnesium compounds per day for adults 0.8 g to 6 g, lg to 10 g, and 40 mg to 600 mg in terms of magnesium Item 13.
- Indigestible saccharides are lactulose, galatato-oligosaccharide, raffinose, stachyose, latatosucrose, furato-oligosaccharide, isomalt-oligosaccharide, xylo-oligosaccharide, palatinose-oligosaccharide, difructose anhydride III, sorbitol, maltitol, lactitol, reduced
- a group power of palatinose and reduced hydrostatic strength is at least one selected, and low-viscosity water-soluble dietary fiber is indigestible dextrin, guagam degradation product, polydextrose, water-soluble soybean polysaccharide, low-molecular alginic acid, and water-soluble corn fiber It is at least one kind selected from the group consisting of one power and is characterized by at least one kind selected from the group power consisting of magnesium compound power magnesium hydroxide, magnesium hydroxide, magnesium si
- Item 15 A method of reducing gastrointestinal transit time characterized by orally administering an amount effective for improving the gastrointestinal transit time of lactulose and magnesium oxide.
- Item 16 Oral dosage power per day for adults of lactulose and magnesium oxalate: 0.8 g to 6 g, and 40 mg to 600 mg in terms of magnesium, respectively. How to lower.
- Item 17 Use of any one of indigestible saccharides, low-viscosity water-soluble food fibers and magnesium compounds to reduce the maximum gastrointestinal transit time.
- Indigestible saccharides are lactulose, galatato-oligosaccharides, raffinose, stachyose, latatosucrose, furato-oligosaccharides, isomalt-oligosaccharides, xylo-oligosaccharides, palatinose-oligosaccharides, difructose anhydride III, sorbitol, maltitol, lactitol, reduced
- a group power of palatinose and reduced hydrostatic strength is at least one selected, and low-viscosity water-soluble dietary fiber is indigestible dextrin, guagam degradation product, polydextrose, water-soluble soybean polysaccharide, low-molecular alginic acid, and water-soluble corn fiber It is at least one selected from the group consisting of one force, magnesium compound power magnesium oxide, hydroxide Item 18. The use according to Item 17, wherein the group power of magnesium, magnesium silicate, and
- Item 19 Use of one of the hard-to-digest saccharides, low-viscosity water-soluble dietary fiber, and magnesium compound to prevent colorectal cancer.
- Indigestible saccharides are lactulose, galatato-oligosaccharide, raffinose, stachyose, latatosucrose, furato-oligosaccharide, isomalt-oligosaccharide, xylo-oligosaccharide, palatinose-oligosaccharide, difructose anhydride III, sorbitol, maltitol, lactitol, reduced
- a group power of palatinose and reduced hydrostatic strength is at least one selected, and low-viscosity water-soluble dietary fiber is indigestible dextrin, guagam degradation product, polydextrose, water-soluble soybean polysaccharide, low-molecular alginic acid, and water-soluble corn fiber It is at least one kind selected from the group consisting of one power and is characterized by at least one kind selected from the group power consisting of magnesium compound power magnesium hydroxide, magnesium hydroxide, magnesium
- Item 21 Use of lactulose and magnesium oxide to reduce gastrointestinal transit time.
- improvement of the maximum gastrointestinal tract passage time means a reduction in the maximum gastrointestinal tract passage time, and is synonymous with the improvement of stool.
- the maximum gastrointestinal transit time and gastrointestinal transit time are shortened and generated from food residues without causing unpleasant side effects such as abdominal fullness, axillary action, and loose stool, particularly fullness. It can suppress the adverse effects on human body due to harmful spoilage products, and can promote the maintenance or promotion of health such as prevention of colorectal cancer. That is, in the present invention, the gastrointestinal transit time can be set to about 17 hours to 70 hours and the maximum gastrointestinal transit time can be set to about 25 hours to 100 hours without feeling abdominal fullness. Furthermore, the maximum gastrointestinal transit time and the range between meals (standard deviation) of the gastrointestinal transit time can be reduced to prevent food residues from staying in the gastrointestinal tract for an extremely long time.
- low-viscosity water-soluble dietary fiber examples include indigestible dextrin, guar gum degradation product, polydextrose, water-soluble soybean polysaccharide, low-molecular alginic acid, and water-soluble corn fiber. Among these, indigestible dextrin or guar gum degradation product is preferable. These low-viscosity water-soluble dietary fibers can be used alone or in combination of two or more, and the intake of healthy adults who are not constipated is preferably lg to 10 g per day. I like it!
- a calcium compound can be further blended.
- Calcium compounds are preferred because they have the effect of alleviating the tendency of loose stool due to magnesium oxide.
- Examples of the calcium compound used in the present invention include calcium carbonate, calcium chloride calcium phosphate, calcium phosphate, calcium lactate, calcium dulconate, calcined shellfish calcium, eggshell strength lucium, dolomite and the like.
- the daily intake of calcium compounds is preferably 10 mg to 1200 mg as the amount of calcium.
- the maximum gastrointestinal transit time improving agent, the gastrointestinal transit time improving agent and the colorectal cancer preventive agent containing a combination of lactulose and magnesium oxide include other indigestible saccharides, low viscosity water-soluble Dietary fiber and a magnesium compound can also be blended.
- the maximum gastrointestinal transit time improving agent, gastrointestinal transit time improving agent and colorectal cancer preventive agent of the present invention include compositions to be administered orally.
- it includes forms such as pharmaceuticals, foods, and supplements.
- the dosage unit form of the maximum gastrointestinal transit time improving agent, gastrointestinal transit time improving agent and colorectal cancer preventive agent of the present invention is not particularly limited as long as it is suitable for oral administration, and can be appropriately selected according to the purpose of administration. . Specific examples include oral preparations such as tablets, coated tablets, powders, granules, capsules, solutions, pills, suspensions, and emulsions. These administration agents are produced by a formulation method generally known in this field.
- the maximum gastrointestinal transit time improving agent, gastrointestinal transit time improving agent and colorectal cancer preventive agent of the present invention are used in a food form, the indigestible saccharide, the low-viscosity water-soluble dietary fiber, or the magnesium compound If necessary, it can be prepared by an ordinary method in combination with an edible carrier, food material, food additive or the like according to its form.
- a food form it can be used as a liquid food such as a beverage, or a solid food such as a tablet, granule, or a chewable tablet. It can also be used as a semi-solid food such as yogurt. It can also be used as health foods, functional foods, foods for specified health use, functional foods for nutrition, foods for the sick, etc.
- Specific food forms include juices, soft drinks, liquid drinks such as tea; powdered drinks such as powdered juice and powdered soup; chocolates, candy, chewing gum, ice cream, jelly, cookies, biscuits, corn flakes, chiyu Confectionery such as tablet tablets, film sheets, wafers, gummi, rice crackers, buns; seasonings such as dressings and sauces; breads, rice cakes, konjac, kneaded products (kamaboko, etc.), sprinkles, oral sprays, lozenges, etc. Can be mentioned. Further, as an additive, live bacteria such as lactic acid bacteria or dead bacteria, other probiotic materials, vitamins, herbal medicines, herbs and other plants themselves or extracts may be blended.
- Examples of the carrier constituting the food include sugar alcohols such as xylitol and erythritol, crystalline cellulose, lactose, sucrose, glucose, starch, carbonates, phosphates and other enhancers, gelatin, alginic acid, Xanthan gum, cellulose, hydroxypropyl cellulose, methylcellulose, carrageenan, pullulan, pectin and other binders, sucrose fatty acid ester, sorbitan fatty acid ester, enzyme-treated lecithin, enzyme-decomposed lecithin, saponin Antioxidants such as ascorbic acid and tocopherol, acidulants such as lactic acid, citrate, darconic acid, glutamic acid, fortifiers such as vitamins, amino acids, lactate, citrate, dalconate, diacid Fluidizing agents such as sucrose, lubricants such as sucrose fatty acid esters, stearates, Kurarosu, acesulfame
- the maximum gastrointestinal transit time improving agent, gastrointestinal transit time improving agent and colorectal cancer preventive agent of the present invention are used in the form of pharmaceuticals, the indigestible saccharide, the low-viscosity water-soluble dietary fiber, or magnesium
- the compound can be prepared by a usual method in combination with a pharmaceutically acceptable carrier, pharmaceutical material, additive and the like according to the form, if necessary.
- the pharmaceutical form include solid preparations such as liquids, tablets, granules, fine granules, and powders, and orally administrable forms such as capsules containing the liquid or solid preparations.
- Examples of the pharmaceutically acceptable carrier include lactose, sucrose, sodium chloride salt, glucose, starch, calcium carbonate, kaolin, crystalline cellulose, kalic acid, methylcellulose, glycerin, sodium alginate, gum arabic, and talc. , Calcium monohydrogen phosphate, calcium hydrogen phosphate, sodium hydrogen phosphate, dipotassium phosphate, potassium dihydrogen phosphate, calcium dihydrogen phosphate, sodium dihydrogen phosphate, calcium sulfate, calcium lactate, strength cocoa butter, etc.
- Excipients simple syrup, glucose solution, starch solution, gelatin solution, polyvinyl alcohol, polyvinyl ether, polyvinyl pyrrolidone, cross polyvinyl pyrrolidone, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, hydroxypropylmethyl cell Loin, hydroxy E chill cellulose, Kano levo carboxy vinyl Honoré polymer, crystal cellulose, powdered cellulose, microcrystalline cellulose 'carmellose sodium, carboxy methylate Roh receptacle Honoré loin, shellac, methylcellulose, E chill cellulose, potassium phosphate, ⁇ Labia gum powder, pullulan, dextrin, corn starch, alpha-monified starch, hydroxypropyl starch, gelatin, xanthan gum, tragacanth, tragacanth powder, macaque glue, dry starch, sodium alginate, agar powder, laminaran powder, bicarbonate Disintegrating agents such as sodium, calcium
- the tablets can be made into tablets with ordinary coatings as necessary, for example, sugar-coated tablets, gelatin-encapsulated tablets, enteric-coated tablets, film-coated tablets, double tablets, multilayer tablets and the like.
- Capsules are prepared by mixing the active ingredient with the various carriers exemplified above and filling hard gelatine capsules, soft capsules, and the like.
- the liquid preparation may be an aqueous or oily suspension, solution, syrup or elixir, and is prepared according to a conventional method using ordinary carriers, additives and the like.
- thickening polysaccharides and dietary fibers can be blended to such an extent that the effect of improving gastrointestinal transit time is not diminished.
- fragrances include heart force oil, eucalyptus oil, keihi oil, wikiyo oil, timber oil, orange oil, lemon oil, rose oil, funole flavor, mint flavor, peppermint powder, dl-menthol, 1 Mentor, etc.
- the administration target of the maximum gastrointestinal transit time improving agent, gastrointestinal transit time improving agent and colorectal cancer preventive agent of the present invention is a healthy person and anxious about the condition of the stomach.
- the person who is concerned about the condition of the stomach is a healthy person who regularly has stool that is not diagnosed as constipation according to the diagnostic criteria for constipation, and the stool is stiffer than the person with normal stool, and the daily The amount of bowel movements is small. Therefore, the subject of administration of the present invention does not include those with constipation.
- those who are worried about the condition of the stomach are those whose defecation frequency per day is 0.5 or more and less than 1.0, and those who are normal in the state of defecation are defecation frequency per day However, those who have constipation are those who regularly defecate and whose defecation frequency per day is less than 0.43.
- a high calorie diet means a caloric intake per day for adults of 35 kcal or more or approximately 2100 kcal or more per kg of body weight.
- the method devised by Hinton et al. was adopted as a method of examining the time to defecation, that is, the time to pass through the digestive tract. Specifically, multiple X-ray contrast-enhanced markers are taken with meals, and the time taken for the marker to be excreted (ti) and the marker contained in the excreted stool based on the X-ray image of the collected stool The number (xi) was determined and the gastrointestinal transit time was calculated from the following formula. Gastrointestinal transit time refers to the average value until several ethasographic contrast markers taken simultaneously are excreted.
- locust bean gum and sirium beet fiber which are considered to have a feasibility improving effect as a dietary fiber, no statistically significant reduction in gastrointestinal transit time and maximum gastrointestinal transit time is observed.
- Katsutsu Locust bean gum and psyllium are water-soluble dietary fibers but have the property of increasing viscosity when dissolved in water.
- Beet fiber is an insoluble dietary fiber. Locust bean gum and psyllium were observed to increase the average defecation volume, but there was no effect of shortening the gastrointestinal transit time and the maximum gastrointestinal transit time.
- the gastrointestinal transit time was shortened while drinking this product to 12 out of 13 people, except for No. 1 person.
- the thirteen pre-drinking gastrointestinal transit time was about 37 hours to about 124 hours, but decreased to about 23 hours to about 70 hours while drinking this product. Compare with the average of 13 people As a result, the gastrointestinal transit time before drinking this product was 67.9 hours, while it was 43.9 hours during drinking, improving the gastrointestinal transit time at a statistical significance level of less than 1%. .
- the maximum gastrointestinal transit time was shortened while taking this product to 12 of 13 people, except for No. 6, one person.
- the maximum gastrointestinal transit time before drinking for about 13 people was about 52 hours to about 151 hours. During drinking this product decreased to about 42 hours to about 98 hours. Comparing the average value of 13 people, the maximum gastrointestinal transit time before drinking this product was 85.2 hours, but it was 63.9 hours while drinking this product, and the statistical significance level was less than 1% The maximum gastrointestinal transit time was improved.
- the average defecation amount per day for 13 subjects increased from 76.2 g before drinking to 117.3 g during drinking at a statistical significance level of less than 5%.
- the shortening of the gastrointestinal transit time and the maximum gastrointestinal transit time of 13 subjects was more prominent in subjects with longer time before drinking.
- no side effects such as diarrhea, loose stool, and abdominal bloating or discomfort were observed. Therefore, this product stays in the gastrointestinal tract for a long time without any pain or discomfort caused by the armpit action! / Reduces the passage time of sour food residues.
- the amount of total spoilage product, the amount of ammonia, the pH, and the amount of water in the stool Nos. 1 to 7 in which the stool samples could be stored at low temperature immediately after defecation were measured.
- phenol, p-cresol, 4E-phenol, indole and skatole were quantified using a gas chromatograph, and the total of these was used as the total spoilage product amount.
- Table 3 shows the total amount of spoilage products and the measurement results of ammonia.
- the pH and water content of feces are shown in Table 4.
- the statistical significance level decreased to 54.5 g, less than 1%.
- the average value of the amount of Ammonia in 7 subjects decreased from 972 gZg before drinking to 593 gZg during drinking at a statistical significance level of less than 1%. From these results, it was shown that the present invention can be expected to prevent colorectal cancer.
- the effect of shortening the gastrointestinal transit time and the maximum gastrointestinal transit time by oral administration of lactulose and magnesium oxide is different from the effect of improving constipation by dietary fiber and oligosaccharides.
- calculating the change in the total amount of spoilage products before and during drinking around the dry weight of feces after removing water the total amount of spoilage products decreased, and the dilution effect due to an increase in the water content in a single stool Turned out not to be.
- a solution having the composition shown in Table 6 was prepared. After the preparation, heat sterilization was performed at 95 ° C for 2 minutes, and 1 OOml was filled into a bottle that could be sealed at a temperature of 85 ° C or higher. * Tightened and cooled in running water. For each 100ml of this product, 2g of resistant sugar and 336mg of magnesium can be ingested.
- the high-calorie diet is 4 retort curry (221kcal.), 5 packed rice (302kcal.) And 80g serial (150kcal.) Per day, totaling 2694kcal.
- the low-calorie diet is 2498 retorts, 3 packs of rice and 40g of cereal per serving, for a total of 1498kcal.
- the high-calorie diet weighs 1920g and the low-calorie diet weighs 1060g.
- a jelly having the following composition was prepared by a conventional method.
- the raw material was heated and dissolved in purified water, sterilized by heating at 95 ° C for 2 minutes, filled with lOOg in a plastic cup, sealed with aluminum, and then cooled in running water.
- This lOOg contains 250mg of magnesium.
- Powdered tea having the following composition was prepared by a conventional method. Each raw material was prepared in a granular form by a fluidized bed granulator. When 5g of this product is dissolved in 180ml of hot water and consumed, 2g of indigestible dextrin and 1.5g of difructose anhydrate III can be ingested.
- Tablets having the following composition were prepared by a conventional method. After the preparation, the tablets were tableted using a rotary continuous tableting machine so that the weight per tablet was 320 mg. By taking 4 to 10 tablets of this product per day, you can ingest about 0.85g to 2.lg as indigestible saccharide and about 186mg to 464mg as magnesium. [0071] Ingredient Compounding amount (% by weight)
- a soft drink having the following composition was prepared by a conventional method. After the preparation, heat sterilization was carried out at 95 ° C for 2 minutes, 160 g of which was filled in a tin can at a temperature of 90 ° C or higher, and then cooled in running water. Per 1 can (160g) of this product, 5.3g of indigestible sugar can be ingested.
- a jelly having the following composition was prepared by a conventional method. This lOOg contains 255 mg magnesium and 50 mg calcium.
- the present invention can be used in fields where the maximum gastrointestinal tract passage time and the digestive tract passage time are required to be shortened. In addition, the present invention can be used in fields that require prevention of colorectal cancer.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05806886A EP1825857A1 (en) | 2004-11-22 | 2005-11-18 | Agent for ameliorating the maximum passage time through digestive tract, agent for ameliorating passage time through digestive tract and preventive for colon cancer |
| JP2006545174A JPWO2006054710A1 (ja) | 2004-11-22 | 2005-11-18 | 最大消化管通過時間改善剤、消化管通過時間改善剤及び大腸癌予防剤 |
| US11/791,166 US20080044493A1 (en) | 2004-11-22 | 2005-11-18 | Agent For Ameliorating The Maximum Passage Time Through Digestive Tract, Agent For Ameliorating Passage Time Through Digestive Tract And Preventive For Colon Cancer |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004368458 | 2004-11-22 | ||
| JP2004-368458 | 2004-11-22 | ||
| JP2005134745 | 2005-05-06 | ||
| JP2005-134745 | 2005-05-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2006054710A1 true WO2006054710A1 (ja) | 2006-05-26 |
Family
ID=36407246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2005/021272 Ceased WO2006054710A1 (ja) | 2004-11-22 | 2005-11-18 | 最大消化管通過時間改善剤、消化管通過時間改善剤及び大腸癌予防剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20080044493A1 (ja) |
| EP (1) | EP1825857A1 (ja) |
| JP (1) | JPWO2006054710A1 (ja) |
| WO (1) | WO2006054710A1 (ja) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2320367C1 (ru) * | 2006-08-22 | 2008-03-27 | Государственное образовательное учреждение дополнительного профессионального образования Российская медицинская академия последипломного образования Федерального агентства по здравоохранению и социальному развитию (ГОУ ДПО РМАПО Росздрава) | Способ сопроводительного лечения острого лимфобластного лейкоза |
| JP2009167172A (ja) * | 2007-12-21 | 2009-07-30 | Nutri Kk | 整腸及び/又は便通改善のための組成物 |
| JP2014532725A (ja) * | 2011-11-06 | 2014-12-08 | エスエスブイ セラピューテクス,リミティド ライアビリティ カンパニー | 下剤および食品サプリメントとしての濃縮プルーンおよびプレバイオティクスの製剤 |
| WO2015076164A1 (ja) * | 2013-11-19 | 2015-05-28 | 日清オイリオグループ株式会社 | 粉末油脂組成物およびその製造方法 |
| WO2016042831A1 (ja) * | 2014-09-18 | 2016-03-24 | 協和化学工業株式会社 | 大腸の検査または手術のための処置用製剤 |
| KR20220120170A (ko) * | 2021-02-23 | 2022-08-30 | 주식회사 핏나인코리아 | 천연물질을 유효성분으로 포함하는 배변활동 개선용 다이어트 식품 조성물 |
| WO2024143197A1 (ja) * | 2022-12-26 | 2024-07-04 | セトラスホールディングス株式会社 | 配合剤及びそれを用いた処置方法 |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006012536A2 (en) | 2004-07-22 | 2006-02-02 | Ritter Andrew J | Methods and compositions for treating lactose intolerance |
| GB2447067A (en) * | 2007-02-20 | 2008-09-03 | Branko R Babic | Alteration of osmotic gradients by polyhydroxy compounds |
| US20110223248A1 (en) * | 2007-12-12 | 2011-09-15 | Ritter Pharmaceuticals, Inc. | Methods and compositions for treating lactose intolerance |
| BE1019158A5 (fr) * | 2009-01-19 | 2012-04-03 | Univ Liege | Procede de production d'une composition, composition et utilisation de celle-ci comme additif alimentaire. |
| CA2752800C (en) | 2009-02-24 | 2017-12-05 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
| WO2011137249A1 (en) * | 2010-04-28 | 2011-11-03 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
| FR2971123B1 (fr) * | 2011-02-08 | 2013-11-22 | Solvay | Galactofructose pour son effet regulateur du transit intestinal |
| JP2014224080A (ja) * | 2013-05-17 | 2014-12-04 | 協和化学工業株式会社 | 大腸の検査または手術のための処置剤 |
| US10806743B1 (en) * | 2017-05-12 | 2020-10-20 | Braintree Laboratories, Inc. | Method of administering lactitol to reduce plasma concentration of lactitol |
| IT202100002204A1 (it) * | 2021-02-02 | 2022-08-02 | Foodar Advanced Res S R L | Composizione per il trattamento della disfagia |
| US20220367050A1 (en) * | 2021-05-12 | 2022-11-17 | Zoe Limited | Predicting gut microbiome diversity |
Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62220169A (ja) * | 1986-03-18 | 1987-09-28 | Yakult Honsha Co Ltd | 流動性食品 |
| JPS6363366A (ja) * | 1986-09-03 | 1988-03-19 | Iwatani & Co | 整腸増進健康食品 |
| JPH01319421A (ja) * | 1988-06-17 | 1989-12-25 | Hajime Inamoto | 食物繊維不足者の便秘改善,便通促進,便性改善用成型物 |
| JPH05255092A (ja) * | 1992-03-17 | 1993-10-05 | Kyowa Hakko Kogyo Co Ltd | 腸管洗浄用組成物 |
| JPH05255097A (ja) * | 1992-01-24 | 1993-10-05 | Miyarisan Seibutsu Igaku Kenkyusho:Kk | 液状組成物 |
| JP2000050843A (ja) * | 1998-08-10 | 2000-02-22 | Morinaga Milk Ind Co Ltd | カルシウム剤、その製造方法、及びカルシウム剤を含 有する食品 |
| JP2001097868A (ja) * | 1999-09-30 | 2001-04-10 | Nippon Beet Sugar Mfg Co Ltd | 排便促進組成物 |
| JP2002051731A (ja) * | 2000-08-11 | 2002-02-19 | Toyo Shinyaku:Kk | 麦若葉由来の素材を含む便秘改善食品 |
| JP2002104980A (ja) * | 2000-09-25 | 2002-04-10 | Takama:Kk | 消化器系運動亢進剤 |
| JP2002223726A (ja) * | 2001-01-31 | 2002-08-13 | Ribateepu Seiyaku Kk | 美容食品 |
| JP2004137194A (ja) * | 2002-10-17 | 2004-05-13 | Fancl Corp | 便通改善組成物 |
| JP2004166639A (ja) * | 2002-11-21 | 2004-06-17 | Tsuboichi Seicha Honpo:Kk | ケール茶 |
| JP2004224777A (ja) * | 2003-01-27 | 2004-08-12 | Hayashibara Biochem Lab Inc | 抗便秘組成物 |
| JP2004292356A (ja) * | 2003-03-27 | 2004-10-21 | Rohto Pharmaceut Co Ltd | 瀉下用製剤 |
-
2005
- 2005-11-18 JP JP2006545174A patent/JPWO2006054710A1/ja active Pending
- 2005-11-18 US US11/791,166 patent/US20080044493A1/en not_active Abandoned
- 2005-11-18 WO PCT/JP2005/021272 patent/WO2006054710A1/ja not_active Ceased
- 2005-11-18 EP EP05806886A patent/EP1825857A1/en not_active Withdrawn
Patent Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62220169A (ja) * | 1986-03-18 | 1987-09-28 | Yakult Honsha Co Ltd | 流動性食品 |
| JPS6363366A (ja) * | 1986-09-03 | 1988-03-19 | Iwatani & Co | 整腸増進健康食品 |
| JPH01319421A (ja) * | 1988-06-17 | 1989-12-25 | Hajime Inamoto | 食物繊維不足者の便秘改善,便通促進,便性改善用成型物 |
| JPH05255097A (ja) * | 1992-01-24 | 1993-10-05 | Miyarisan Seibutsu Igaku Kenkyusho:Kk | 液状組成物 |
| JPH05255092A (ja) * | 1992-03-17 | 1993-10-05 | Kyowa Hakko Kogyo Co Ltd | 腸管洗浄用組成物 |
| JP2000050843A (ja) * | 1998-08-10 | 2000-02-22 | Morinaga Milk Ind Co Ltd | カルシウム剤、その製造方法、及びカルシウム剤を含 有する食品 |
| JP2001097868A (ja) * | 1999-09-30 | 2001-04-10 | Nippon Beet Sugar Mfg Co Ltd | 排便促進組成物 |
| JP2002051731A (ja) * | 2000-08-11 | 2002-02-19 | Toyo Shinyaku:Kk | 麦若葉由来の素材を含む便秘改善食品 |
| JP2002104980A (ja) * | 2000-09-25 | 2002-04-10 | Takama:Kk | 消化器系運動亢進剤 |
| JP2002223726A (ja) * | 2001-01-31 | 2002-08-13 | Ribateepu Seiyaku Kk | 美容食品 |
| JP2004137194A (ja) * | 2002-10-17 | 2004-05-13 | Fancl Corp | 便通改善組成物 |
| JP2004166639A (ja) * | 2002-11-21 | 2004-06-17 | Tsuboichi Seicha Honpo:Kk | ケール茶 |
| JP2004224777A (ja) * | 2003-01-27 | 2004-08-12 | Hayashibara Biochem Lab Inc | 抗便秘組成物 |
| JP2004292356A (ja) * | 2003-03-27 | 2004-10-21 | Rohto Pharmaceut Co Ltd | 瀉下用製剤 |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2320367C1 (ru) * | 2006-08-22 | 2008-03-27 | Государственное образовательное учреждение дополнительного профессионального образования Российская медицинская академия последипломного образования Федерального агентства по здравоохранению и социальному развитию (ГОУ ДПО РМАПО Росздрава) | Способ сопроводительного лечения острого лимфобластного лейкоза |
| JP2009167172A (ja) * | 2007-12-21 | 2009-07-30 | Nutri Kk | 整腸及び/又は便通改善のための組成物 |
| JP2016172761A (ja) * | 2007-12-21 | 2016-09-29 | ニュートリー株式会社 | 整腸及び/又は便通改善のための組成物 |
| JP2014532725A (ja) * | 2011-11-06 | 2014-12-08 | エスエスブイ セラピューテクス,リミティド ライアビリティ カンパニー | 下剤および食品サプリメントとしての濃縮プルーンおよびプレバイオティクスの製剤 |
| WO2015076164A1 (ja) * | 2013-11-19 | 2015-05-28 | 日清オイリオグループ株式会社 | 粉末油脂組成物およびその製造方法 |
| JP5892295B2 (ja) * | 2013-11-19 | 2016-03-23 | 日清オイリオグループ株式会社 | 粉末油脂組成物およびその製造方法 |
| WO2016042831A1 (ja) * | 2014-09-18 | 2016-03-24 | 協和化学工業株式会社 | 大腸の検査または手術のための処置用製剤 |
| KR20220120170A (ko) * | 2021-02-23 | 2022-08-30 | 주식회사 핏나인코리아 | 천연물질을 유효성분으로 포함하는 배변활동 개선용 다이어트 식품 조성물 |
| KR102614356B1 (ko) | 2021-02-23 | 2023-12-14 | 주식회사 핏나인코리아 | 천연물질을 유효성분으로 포함하는 배변활동 개선용 다이어트 식품 조성물 |
| WO2024143197A1 (ja) * | 2022-12-26 | 2024-07-04 | セトラスホールディングス株式会社 | 配合剤及びそれを用いた処置方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1825857A1 (en) | 2007-08-29 |
| US20080044493A1 (en) | 2008-02-21 |
| JPWO2006054710A1 (ja) | 2008-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6882931B2 (ja) | プレバイオティック製剤および使用方法 | |
| WO2006054710A1 (ja) | 最大消化管通過時間改善剤、消化管通過時間改善剤及び大腸癌予防剤 | |
| KR101947720B1 (ko) | 위 및 결장 조제물 및 이의 제조 및 사용 방법 | |
| JP4793533B2 (ja) | ポリデキストロースでの免疫系の刺激 | |
| JP3065648B2 (ja) | L―糖緩下薬 | |
| EP2797606A2 (en) | Composition and use of a formulation to increase the ratio of gastrointestinal microbiota in phylum bacteriodites to microbiota of firmuctes phylum | |
| JP4162147B2 (ja) | アレルギー抑制剤 | |
| AU2005290262A1 (en) | Compositions having body fat reducing function and food and drink containing the same | |
| NO320546B1 (no) | Prebiotiske kombinasjonsprodukter | |
| JPH05255097A (ja) | 液状組成物 | |
| BE1025428B1 (nl) | Voedingssupplement en gebruiken daarvan | |
| JPWO2008053984A1 (ja) | アロエおよび寒天を含有した健康食品 | |
| JP6650728B2 (ja) | ダイエット用の製剤 | |
| JPWO2010104175A1 (ja) | 経口用組成物 | |
| WO2009113594A1 (ja) | 機能性消化管障害予防・改善剤および食品 | |
| US20070259094A1 (en) | N-acetylglucosamine as a food and beverage additive | |
| CN112912070A (zh) | 夜间多尿的治疗或预防剂 | |
| JP7057039B2 (ja) | 認知症の予防又は改善用剤及びそれを含む組成物 | |
| JP2007131541A (ja) | 成長ホルモン分泌促進剤 | |
| JPH11147828A (ja) | コレステロール及び脂質吸収阻害剤 | |
| JP2018153166A (ja) | 筋肉量増加用組成物、体脂肪低下用組成物、並びに筋肉量増加及び体脂肪低下用組成物 | |
| JP4721684B2 (ja) | ダイフラクトースアンハイドライド含有経口組成物 | |
| JP2021100421A (ja) | 肝機能改善用組成物及び肝機能改善用食品組成物 | |
| JP7063514B2 (ja) | 起立性低血圧の予防又は改善用剤及びそれを含む組成物 | |
| WO2008080810A2 (en) | Composition comprising cocoa fibre |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2006545174 Country of ref document: JP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 11791166 Country of ref document: US |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2005806886 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 2005806886 Country of ref document: EP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 2005806886 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 11791166 Country of ref document: US |